Enable JavaScript to visit this website.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.


XELJANZ/​XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:

  • Adults with moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated

It is not known if XELJANZ/​XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.

XELJANZ/​XELJANZ XR is not recommended for people with severe liver problems.

XELJANZ XR is a pill, not an injection or infusion.

XELJANZ XR is the first and only FDA-approved once-daily pill for adults with moderate to severe UC in whom tumor necrosis factor (TNF) blockers did not work well enough or cannot be tolerated.

Results from clinical trials show:*

  • Reduced some symptoms in as early as 2 weeks. Individual results may vary. Symptoms include rectal bleeding and stool frequency.
  • Improved the appearance of the intestinal lining.
  • Provided lasting steroid-free remission.

*Efficacy and safety of XELJANZ were tested in 3 double-blind, placebo-controlled clinical studies in adult patients with moderate to severe ulcerative colitis. In each study, participants were given either XELJANZ or a sugar pill (placebo). Assessments of intestinal lining were conducted at 8 and 52 weeks. Assessment of sustained steroid-free remission was conducted at 24 and 52 weeks for those patients in remission at the beginning of the study.

Ask your doctor if XELJANZ—or once-daily, extended-release XELJANZ XR—may be right for you.

once-daily pill, not an
injection or infusion

Are you 18 or older? Have you been diagnosed with moderate to severe ulcerative colitis and have you taken a TNF blocker in the past? Have you been prescribed XELJANZ? We want to hear from you! Your stories are important - particularly for adult patients who are considering treatment or those who have just started. If selected, your story may appear in XELJANZ.com and/or in other marketing materials. Certain criteria must be met for consideration. Email us at [email protected] or call 877-744-3356.